drugset / Trial / NCT01223924

Single-dose Escalation Trial of M2ES in Healthy Volunteer

NCT01223924 ↗

Phase 1 Completed 33 enrolled Protgen Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized double-blinded placebo-controlled,single-dose escalation trial in healthy volunteer.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject M2ES Protein / enzyme biologic 7.5 mg Intravenous
Subject M2ES Protein / enzyme biologic 90 mg Intravenous

Indications